M
Mariam Semmo
Researcher at University of Bern
Publications - 9
Citations - 177
Mariam Semmo is an academic researcher from University of Bern. The author has contributed to research in topics: Type 2 diabetes & Tolvaptan. The author has an hindex of 6, co-authored 9 publications receiving 118 citations.
Papers
More filters
Journal ArticleDOI
Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis
Lia Bally,Lia Bally,Philipp Gubler,Hood Thabit,Hood Thabit,Hood Thabit,Sara Hartnell,Yue Ruan,Yue Ruan,Malgorzata E. Wilinska,Mark L. Evans,Mark L. Evans,Mariam Semmo,Bruno Vogt,Anthony P. Coll,Anthony P. Coll,Christoph Stettler,Roman Hovorka +17 more
TL;DR: In this paper, the authors compared the efficacy of fully automated closed-loop insulin delivery vs. usual care in patients undergoing hemodialysis while in hospital and found that those patients receiving closed loop insulin delivery significantly increased the proportion of time when a continuous glucose monitor was in the target range of 5.6-10.0 mmol/l by 37.6 percent without increasing the risk of hypoglycemia.
Journal ArticleDOI
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
TL;DR: This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.
Journal ArticleDOI
Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.
Eleonora Patsenker,Philip Sachse,Andrea Chicca,María Salomé Gachet,Vreni Schneider,Johan Mattsson,Christian Lanz,Mathias Worni,Andrea De Gottardi,Mariam Semmo,Jochen Hampe,Clemens Schafmayer,Rudolf Brenneisen,Jürg Gertsch,Felix Stickel,Nasser Semmo +15 more
TL;DR: ECs are increased in plasma of patients with CHC and might reveal immunosuppressive and profibrogenic effects.
Journal ArticleDOI
T- and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients.
Q Wang,Q Wang,P Sachse,Mariam Semmo,M.U. Lokhande,Matteo Montani,Jean-François Dufour,Fabien Zoulim,Paul Klenerman,Nasser Semmo +9 more
TL;DR: ‘Anti‐HBc alone’ individuals showed HBV‐specific T‐cell and memory B‐cell responses typical of previous viral exposure and protective memory, suggesting a resolved infection.
Journal ArticleDOI
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
Manuel Anderegg,Nasser A. Dhayat,Grit Sommer,Mariam Semmo,Uyen Huynh-Do,Bruno Vogt,Daniel Guido Fuster +6 more
TL;DR: The results indicate that tolvaptan does not significantly affect HRQoL in patients with ADPKD who tolerate treatment beyond the first 3 months of therapy, except for patient satisfaction, which was increased.